LDLR and atherosclerosis: Silverman et al. [7] later established that LDL-C lowering by non-statin interventions that work primarily via upregulation of LDL receptor expression, e.g., ezetimibe treatment, reduces the risk of ASCVD events to a similar degree as statin treatment.